Area:
Immunology, Oncology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Albert Gutierrez is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2009 — 2011 |
Gutierrez, Albert |
F31Activity Code Description: To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward the research degree (e.g., Ph.D.). |
The Role of the Wnt Signaling Pathway in B-Cll Biology
DESCRIPTION (provided by applicant): The canonical Wnt signaling pathway is well documented to be pathogenic in a variety of cancers. We hypothesize that this pathway is also at work in B cell-chronic lymphocytic leukemia (B-CLL). In preliminary studies we have identified a number of factors that suggest a functional relevance of the Wnt signaling pathway in B-CLL biology. The studies we propose would demonstrate mechanistically and functionally the relevance of this pathway in B-CLL and identify the therapuetic potential in blocking the pathway in this disease. To understand how the Wnt pathway functions in B-CLL, we will conduct research for the following Aims: 1) We will identify the mechanism(s) of Wnt pathway activation in B-CLL. We will use Wnt qPCR arrays, western blotting, flow cytometry and confocal microscopy to fully characterize the Wnt pathway and its signaling intermediates in leukemic B cells. 2) Test the hypothesis that the p-catenin/LEF-1 complex is activated and critical for CLL B cell survival. We will characterize Wnt transcription factor activation using TOP/Flash luciferase assay and confocal microscopy. To determine the effect on leukemic survival we will use a small molecule inhibitor of the Wnt pathway and siRNA mediated knockdown of Wnt transcription factors. 3) Test the hypothesis that the p-catenin/LEF-1 complex is a key transcriptional regulator of oncogenic genes. We will use chromatin immunoprecipitation (ChIP) and microarray analysis to identify genes regulated by this pathway. Through these studies, we aim to add novel insight into the etiology of this disease and are optimistic that this information can be used to devise timely novel therapeutic interventions. B cell chronic lymphocytic leukemia is a very common leukemia in this country and is currently incurable. Because at least 70 percent of all patients will ultimately require treatment in order to have an enhanced quality of life and increased survival, we are committed to better understanding the underlying mechanisms that contribute to leukemic cell growth and survival. This proposal will take a comprehensive approach to define the role of the Wnt signaling pathway in determining the behavior of the malignant B cells and how this in turn dictates patient clinical outcome.
|
0.954 |